Patents by Inventor Achyutharao Sidduri

Achyutharao Sidduri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoidide derivatives and methods of making and using same
    Patent number: 11964987
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 23, 2024
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Achyutharao Sidduri
  • Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
    Patent number: 11491178
    Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (? V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: November 8, 2022
    Assignee: HOFFMANN-LA ROCHE, INC.
    Inventors: Jayne Chin, Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Achyutharao Sidduri
  • ISOIDIDE DERIVATIVES AND METHODS OF MAKING AND USING SAME
    Publication number: 20210002291
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Application
    Filed: September 22, 2020
    Publication date: January 7, 2021
    Inventor: Achyutharao Sidduri
  • Isoidide derivatives and methods of making and using same
    Patent number: 10815244
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 27, 2020
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventor: Achyutharao Sidduri
  • SOLUBILITY FOR TARGET COMPOUNDS
    Publication number: 20190382414
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Application
    Filed: August 26, 2019
    Publication date: December 19, 2019
    Inventor: Achyutharao Sidduri
  • CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY
    Publication number: 20180099005
    Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (? V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.
    Type: Application
    Filed: November 14, 2017
    Publication date: April 12, 2018
    Inventors: Jayne Chin, JR., Robert Alan Goodnow, JR., Matthew Michael Hamilton, Achyutharao Sidduri
  • Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Publication number: 20170290834
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: November 28, 2016
    Publication date: October 12, 2017
    Inventors: Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Helmut BUSCHMANN, Stephen CUSACK, Mark SMITH, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • Integrin antagonist conjugates for targeted delivery to cells expressing LFA-1
    Patent number: 9650363
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to LFA-1 integrin antagonists to target cells expressing LFA-1.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: May 16, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Agnieszka Kowalczyk, Achyutharao Sidduri
  • SOLUBILITY FOR TARGET COMPOUNDS
    Publication number: 20170066778
    Abstract: The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epidermal growth factor receptor (EGRF) inhibitors, kinase inhibitors and prodrugs of alpha4 beta1 and alpha4 beta7 integrin antagonists.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 9, 2017
    Applicant: Aunova Medchem LLC
    Inventor: Achyutharao Sidduri
  • Integrin antagonist conjugates for targeted delivery to cells expressing alpha-V-beta-3
    Patent number: 9586916
    Abstract: The invention relates to compounds of formula (I): wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (I) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-V-beta-3 integrin antagonists to target cells expressing alpha-V-beta-3.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: March 7, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Agnieszka Kowalczyk, Achyutharao Sidduri
  • Substituted 1,5-naphthyridines as endonuclease inhibitors
    Patent number: 9505758
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: November 29, 2016
    Assignees: Savira pharmaceuticals GmbH, F. Hoffman-La Roche AG, European Molecular Biology Laboratory
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
    Patent number: 9447035
    Abstract: The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: September 20, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Achyutharao Sidduri
  • N-alkyltriazole compounds as LPAR antagonists
    Patent number: 9321738
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 26, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Stephen Deems Gabriel, Matthew Michael Hamilton, Matthew C. Lucas, Yimin Qian, Achyutharao Sidduri
  • NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
    Publication number: 20160039818
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 22, 2015
    Publication date: February 11, 2016
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease
    Patent number: 9199987
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: December 1, 2015
    Assignees: Savira pharmaceuticals GmbH, European Molecular Biology Laboratory, F. Hoffmann-La Roche AG
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri
  • CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY
    Publication number: 20150306130
    Abstract: The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (?4?1) and alpha-V-beta-3 (?V?3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.
    Type: Application
    Filed: January 24, 2013
    Publication date: October 29, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jayne CHIN, Robert Alan Goodnow, JR., Matthew Michael Hamilton, Achyutharao Sidduri
  • LPAR—substituted cyanopyrazole compounds
    Patent number: 9169215
    Abstract: Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such pulmonary fibrosis.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: October 27, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: David Budd, Yimin Qian, Ryan Craig Schoenfeld, Achyutharao Sidduri
  • SUBSTITUTED PYRAZOLE COMPOUNDS AS LPAR ANTAGONISTS
    Publication number: 20150259295
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification.
    Type: Application
    Filed: June 17, 2013
    Publication date: September 17, 2015
    Inventors: Stephen Deems Gabriel, Matthew Michael Hamilton, Yimin Qian, Achyutharao Sidduri
  • LPAR - SUBSTITUTED CYANOPYRAZOLE COMPOUNDS
    Publication number: 20150218106
    Abstract: Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such pulmonary fibrosis.
    Type: Application
    Filed: September 2, 2013
    Publication date: August 6, 2015
    Inventors: David Budd, Yimin Qian, Ryan Craig Schoenfeld, Achyutharao Sidduri
  • Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
    Patent number: 9045486
    Abstract: The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: June 2, 2015
    Assignees: Savira pharmaceuticals GmbH, European Molecular Biology Laboratory, F. Hoffman-La Roche AG
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Helmut Buschmann, Stephen Cusack, Mark Smith, Sung-Sau So, Ronald Charles Hawley, Achyutharao Sidduri, Zhuming Zhang